Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daratumumab + Dexamethasone + Lenalidomide |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daratumumab | Darzalex | JNJ-54767414 | CD38 Antibody 20 | Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov). |
| Dexamethasone | Adexone | Desametasone | ||
| Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05552222 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide + Teclistamab | A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7) | Recruiting | TUR | SWE | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 4 |
| NCT03937635 | Phase III | Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Recruiting | USA | 1 |
| NCT04151667 | Phase II | Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Lenalidomide | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT06550895 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Talquetamab-tgvs | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (MonumenTAL-8) | Recruiting | USA | AUS | 0 |
| NCT04140162 | Phase II | Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy | Active, not recruiting | USA | 0 |
| NCT05438043 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide Daratumumab Carfilzomib + Daratumumab + Dexamethasone | A Study of Daratumumab | Recruiting | USA | POL | ITA | GRC | FRA | ESP | DNK | DEU | BEL | 4 |
| NCT03412565 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | Completed | USA | ISR | GBR | FRA | ESP | DEU | CZE | BRA | 1 |
| NCT04566328 | Phase III | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Recruiting | USA | 1 |
| NCT05623020 | Phase III | Daratumumab + Elranatamab-bcmm + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6) | Recruiting | POL | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CAN | AUS | 3 |
| NCT03652064 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Active, not recruiting | USA | TUR | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | 1 |
| NCT04635189 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT03993912 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide | Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03) | Active, not recruiting | FRA | 0 |
| NCT06182774 | Phase III | Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma | Recruiting | CAN | 0 |
| NCT04223661 | Phase II | Daratumumab + Dexamethasone + Lenalidomide | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | Withdrawn | USA | 0 |
| NCT06187441 | Phase III | Daratumumab + Dexamethasone + Lenalidomide | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM) | Recruiting | NLD | 0 |
CKB BOOST